We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-1.61%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$21M
(+22%)
Cap. Flow
+$284M
Cap. Flow
% of AUM
244.1%
Top 10 Holdings %
Top 10 Hldgs %
42.12%
Holding
462
New
171
Increased
79
Reduced
68
Closed
122
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$4.59M |
| 2 |
Biogen
BIIB
|
+$3.56M |
| 3 |
Cal-Maine
CALM
|
+$2.79M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$2.48M |
| 5 |
Apple
AAPL
|
+$2.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$4.11M |
| 2 |
Gilead Sciences
GILD
|
+$2M |
| 3 |
IBM
IBM
|
+$1.48M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$930K |
| 5 |
Expedia Group
EXPE
|
+$914K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 41.4% |
| 2 | Technology | 6.27% |
| 3 | Consumer Staples | 4.14% |
| 4 | Consumer Discretionary | 2.26% |
| 5 | Materials | 1.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
PUT
Insmed
INSM
$23.5B
| $100K | 0.09% |
+30,000
| New | +$350K |
|
152
Yum! Brands
YUM
$40.8B
| $100K | 0.09% |
+1,669
| New | +$98.4K |
|
|
MON
153
CALL
DELISTED
Monsanto Co
MON
| $98K | 0.08% |
31,100
+6,100
| +24% | +$604K |
|
154
CALL
Coca-Cola
KO
$351B
| $97K | 0.08% |
180,900
-201,100
| -53% | -$9.09M |
|
|
AGN
155
PUT
DELISTED
Allergan plc
AGN
| $96K | 0.08% |
+10,000
| New | +$2.31M |
|
156
Alibaba
BABA
$276B
| $95K | 0.08% |
+1,200
| New | +$93.9K |
|
|
NIHD
157
DELISTED
NII Holdings, Inc. Common Stock
NIHD
| $95K | 0.08% |
30,000
+20,000
| +200% | +$83.9K |
|
158
Bank OZK
OZK
$5.68B
| $94K | 0.08% |
+2,500
| New | +$98.5K |
|
159
Heron Therapeutics
HRTX
$89.1M
| $93K | 0.08% |
+5,156
| New | +$101K |
|
|
160
CALL
IBM
IBM
$200B
| $91K | 0.08% |
+13,075
| New | +$1.87M |
|
161
PUT
Alnylam Pharmaceuticals
ALNY
$35.7B
| $90K | 0.08% |
30,000
-15,000
| -33% | -$945K |
|
162
PUT
BioMarin Pharmaceuticals
BMRN
$11.5B
| $90K | 0.08% |
+44,600
| New | +$3.79M |
|
163
DuPont de Nemours
DD
$18.3B
| $90K | 0.08% |
+714
| New | +$93.9K |
|
164
CALL
Abbott
ABT
$175B
| $89K | 0.08% |
11,500
+3,500
| +44% | +$139K |
|
165
PUT
Alaunos Therapeutics
TCRT
$5.01M
| $88K | 0.08% |
+667
| New | +$726K |
|
166
CALL
Kohl's
KSS
$1.96B
| $85K | 0.07% |
+30,000
| New | +$1.19M |
|
167
Procter & Gamble
PG
$349B
| $85K | 0.07% |
+1,000
| New | +$82.1K |
|
168
PUT
Ulta Beauty
ULTA
$20.6B
| $83K | 0.07% |
+9,500
| New | +$2.07M |
|
169
CALL
Cigna
CI
$74.5B
| $82K | 0.07% |
32,600
+10,000
| +44% | +$1.32M |
|
170
Synaptics
SYNA
$4.46B
| $80K | 0.07% |
+1,480
| New | +$102K |
|
|
BLUE
171
PUT
DELISTED
bluebird bio
BLUE
| $79K | 0.07% |
826
| – | – |
|
172
CALL
Intel
INTC
$478B
| $78K | 0.07% |
53,200
+32,300
| +155% | +$1.01M |
|
|
173
CALL
Gilead Sciences
GILD
$167B
| $77K | 0.07% |
47,300
-34,800
| -42% | -$3.09M |
|
|
FLNA
174
Filana Therapeutics
FLNA
$51.2M
| $77K | 0.07% |
+5,037
| New | +$79.9K |
|
|
WWAV
175
PUT
DELISTED
The WhiteWave Foods Company
WWAV
| $76K | 0.07% |
+30,900
| New | +$1.33M |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q2 2016 Portfolio in Review
As of Q2 2016, FT Options held 462 positions worth $116M, up 22% from $95.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
FT Options deployed $284M of net new capital in Q2 2016, opening 171 new positions and adding to 79 existing holdings. Its largest new stake was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was Gilead Sciences, an estimated $2M trimmed.
- FT Options's largest Q2 2016 buy was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
- FT Options added most to MEDIVATION, INC. in Q2 2016, an estimated $4.59M increase.
- FT Options's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $2M.
- FT Options fully exited Baxter International in Q2 2016, selling an estimated $4.11M.
- FT Options's ten largest holdings make up 42% of its $116M portfolio in Q2 2016.
- FT Options opened 171 new positions and closed 122 in Q2 2016.
- FT Options's portfolio value rose 22% quarter-over-quarter to $116M.
Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.